165 related articles for article (PubMed ID: 16855786)
41. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Chang CJ; Yang JY; Xia W; Chen CT; Xie X; Chao CH; Woodward WA; Hsu JM; Hortobagyi GN; Hung MC
Cancer Cell; 2011 Jan; 19(1):86-100. PubMed ID: 21215703
[TBL] [Abstract][Full Text] [Related]
42. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
[TBL] [Abstract][Full Text] [Related]
43. Deregulated Polycomb functions in myeloproliferative neoplasms.
Sashida G; Oshima M; Iwama A
Int J Hematol; 2019 Aug; 110(2):170-178. PubMed ID: 30706327
[TBL] [Abstract][Full Text] [Related]
44. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
45. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
46. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
[TBL] [Abstract][Full Text] [Related]
47. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
[TBL] [Abstract][Full Text] [Related]
48. HDAC inhibitors conquer Polycomb proteins.
Yaswen P
Cell Cycle; 2010 Jul; 9(14):2705. PubMed ID: 20676029
[No Abstract] [Full Text] [Related]
49. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
[TBL] [Abstract][Full Text] [Related]
50. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Ougolkov AV; Bilim VN; Billadeau DD
Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
Yoon KA; Gil HJ; Han J; Park J; Lee JS
J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
[TBL] [Abstract][Full Text] [Related]
52. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells.
Reynolds PA; Sigaroudinia M; Zardo G; Wilson MB; Benton GM; Miller CJ; Hong C; Fridlyand J; Costello JF; Tlsty TD
J Biol Chem; 2006 Aug; 281(34):24790-802. PubMed ID: 16766534
[TBL] [Abstract][Full Text] [Related]
53. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA
Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070
[TBL] [Abstract][Full Text] [Related]
54. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.
Avissar-Whiting M; Koestler DC; Houseman EA; Christensen BC; Kelsey KT; Marsit CJ
Epigenetics; 2011 Jun; 6(6):703-9. PubMed ID: 21610323
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of SIRT1 increases EZH2 protein level and enhances the repression of EZH2 on target gene expression.
Lu L; Li L; Lü X; Wu XS; Liu DP; Liang CC
Chin Med Sci J; 2011 Jun; 26(2):77-84. PubMed ID: 21703114
[TBL] [Abstract][Full Text] [Related]
56. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer.
Friedman JM; Jones PA; Liang G
Cell Cycle; 2009 Aug; 8(15):2313-4. PubMed ID: 19625769
[No Abstract] [Full Text] [Related]
57. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
[TBL] [Abstract][Full Text] [Related]
58. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.
Ciarapica R; Russo G; Verginelli F; Raimondi L; Donfrancesco A; Rota R; Giordano A
Cell Cycle; 2009 Jan; 8(1):172-5. PubMed ID: 19106613
[No Abstract] [Full Text] [Related]
59. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
Yu J; Cao Q; Yu J; Wu L; Dallol A; Li J; Chen G; Grasso C; Cao X; Lonigro RJ; Varambally S; Mehra R; Palanisamy N; Wu JY; Latif F; Chinnaiyan AM
Oncogene; 2010 Sep; 29(39):5370-80. PubMed ID: 20622896
[TBL] [Abstract][Full Text] [Related]
60. Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Kleer CG
Arch Pathol Lab Med; 2009 Nov; 133(11):1822-5. PubMed ID: 19886718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
